Literature DB >> 16414208

Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer.

Stephanie T H Peeters1, Joos V Lebesque, Wilma D Heemsbergen, Wim L J van Putten, Annerie Slot, Michel F H Dielwart, Peter C M Koper.   

Abstract

PURPOSE: To identify dosimetric parameters derived from anorectal, rectal, and anal wall dose distributions that correlate with different late gastrointestinal (GI) complications after three-dimensional conformal radiotherapy for prostate cancer. METHODS AND MATERIALS: In this analysis, 641 patients from a randomized trial (68 Gy vs. 78 Gy) were included. Toxicity was scored with adapted Radiation Therapy Oncology Group/European Organization for the Research and Treatment of Cancer (RTOG/EORTC) criteria and five specific complications. The variables derived from dose-volume histogram of anorectal, rectal, and anal wall were as follows: % receiving > or =5-70 Gy (V5-V70), maximum dose (Dmax), and mean dose (D(mean)). The anus was defined as the most caudal 3 cm of the anorectum. Statistics were done with multivariate Cox regression models. Median follow-up was 44 months.
RESULTS: Anal dosimetric variables were associated with RTOG/EORTC Grade > or =2 (V5-V40, D(mean)) and incontinence (V5-V70, D(mean)). Bleeding correlated most strongly with anorectal V55-V65, and stool frequency with anorectal V40 and D(mean). Use of steroids was weakly related to anal variables. No volume effect was seen for RTOG/EORTC Grade > or =3 and pain/cramps/tenesmus.
CONCLUSION: Different volume effects were found for various late GI complications. Therefore, to evaluate the risk of late GI toxicity, not only intermediate and high doses to the anorectal wall volume should be taken into account, but also the dose to the anal wall.

Entities:  

Mesh:

Year:  2006        PMID: 16414208     DOI: 10.1016/j.ijrobp.2005.10.002

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  47 in total

1.  Dosimetric planning study for the prevention of anal complications after post-operative whole pelvic radiotherapy in cervical cancer patients with hemorrhoids.

Authors:  J G Baek; E C Kim; S K Kim; H Jang
Journal:  Br J Radiol       Date:  2015-09-23       Impact factor: 3.039

2.  Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues.

Authors:  Søren M Bentzen; Louis S Constine; Joseph O Deasy; Avi Eisbruch; Andrew Jackson; Lawrence B Marks; Randall K Ten Haken; Ellen D Yorke
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

3.  The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome.

Authors:  Andrew Jackson; Lawrence B Marks; Søren M Bentzen; Avraham Eisbruch; Ellen D Yorke; Randal K Ten Haken; Louis S Constine; Joseph O Deasy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

4.  The impact of androgen deprivation therapy on setup errors during external beam radiation therapy for prostate cancer.

Authors:  Cem Onal; Yemliha Dolek; Yurday Ozdemir
Journal:  Strahlenther Onkol       Date:  2017-04-13       Impact factor: 3.621

5.  Incidence of late rectal bleeding in high-dose conformal radiotherapy of prostate cancer using equivalent uniform dose-based and dose-volume-based normal tissue complication probability models.

Authors:  Matthias Söhn; Di Yan; Jian Liang; Elisa Meldolesi; Carlos Vargas; Markus Alber
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-01-26       Impact factor: 7.038

6.  Is it essential to use fiducial markers during cone-beam CT-based radiotherapy for prostate cancer patients?

Authors:  Berna A Yildirim; Cem Onal; Yemliha Dolek
Journal:  Jpn J Radiol       Date:  2016-10-11       Impact factor: 2.374

7.  Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial.

Authors:  Jeff M Michalski; Yan Yan; Deborah Watkins-Bruner; Walter R Bosch; Kathryn Winter; James M Galvin; Jean-Paul Bahary; Gerard C Morton; Matthew B Parliament; Howard M Sandler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-10-08       Impact factor: 7.038

8.  The contribution of the cone beam Kv CT (CBKvCT) to the reduction in toxicity of prostate cancer treatment with external 3D radiotherapy.

Authors:  Antonio José Conde-Moreno; Carlos Ferrer-Albiach; Mercedes Zabaleta-Meri; Xavi J Juan-Senabre; Agustín Santos-Serra
Journal:  Clin Transl Oncol       Date:  2012-10-02       Impact factor: 3.405

Review 9.  Reducing rectal injury during external beam radiotherapy for prostate cancer.

Authors:  Riccardo Valdagni; Tiziana Rancati
Journal:  Nat Rev Urol       Date:  2013-05-14       Impact factor: 14.432

10.  Dose/volume-response relations for rectal morbidity using planned and simulated motion-inclusive dose distributions.

Authors:  Maria Thor; Aditya Apte; Joseph O Deasy; Àsa Karlsdóttir; Vitali Moiseenko; Mitchell Liu; Ludvig Paul Muren
Journal:  Radiother Oncol       Date:  2013-11-11       Impact factor: 6.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.